RxDoctor Payments Data

Sandra Maldonado-Rivera, MD

Infectious Disease · San Juan, PRNPI 1891980892

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (58.3%), food and beverage and education — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Gilead at 40.4% of the total. Reporting peaked in 2019 at $1,076 and has fallen 97.9% since, to $23 in 2024.

$3,089in general payments, 2019–2025

Across 58 payments — averaging $53.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1K
  • AbbVie$808
  • Johnson & Johnson$341
  • Merck$251
  • Viiv Healthcare Company$228
  • Janssen Products, LP$100
  • plus $114 from 2 others

What the payments were for

  • Consulting fees$1,80058%
  • Food & beverage$1,14137%
  • Education$1485%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead13$1,247
AbbVie(2 entities)3$808
Johnson & Johnson16$341
Merck9$251
Viiv Healthcare Company11$228
Janssen Products, LP1$100
E.r. Squibb & Sons, L.L.C.4$89
PBG Puerto Rico LLC1$25

How this compares

$3,089 in reported general payments places this provider in the 75th percentile of 127 infectious disease providers in Puerto Rico.

See all infectious disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$3,218
Medicare patients
12
Services billed
29

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Omega-3 Acid Ethyl Esters18$634

Paid to pharmacies, not to this prescriber.

Other infectious disease in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →